Global Theranostics Market to Grow at 16.4% During 2025-2033, Impelled by Increasing Prevalence of Cancer

January 16, 2025 | Healthcare

According to the latest report by IMARC Group, titled "Theranostics Market Report by Disease Type (Neurological Disorders, Cardiovascular Diseases, Immunological Disorders, Oncology Diseases, and Others), Technology (Polymerase Chain Reaction, Immunohistochemistry, In-Situ Hybridization, Sequencing, and Others), End User (Hospitals and Clinics, Diagnostic Laboratories, and Others), and Region 2025-2033," the global theranostics market size reached USD 2.3 Billion in 2024. Theranostics is the term used to describe the mixture of diagnostic biomarkers with therapeutic agents that share a specific target in diseased cells or tissues. It is derived from a combination of the words therapeutics and diagnostics. In this, drugs are uniquely combined to diagnose and treat medical conditions simultaneously. It provides a transition from traditional to personalized medicines. It deals with a customized treatment plan based on the uniqueness of every person, thus resulting in the right drug for the right patient at the right time. It helps to avoid unnecessary therapies being given to patients for whom they are unsuitable and ensure that the planned treatment will influence the targeted therapy area effectively. Theranostics is a new medical field that is gaining much attention from regulatory authorities and the healthcare industry.

Global Theranostics Market Trends:

The global market is majorly driven by the increasing incidences of cancer and other chronic illness. In line with this, the rising investments in biological research and the growing number of approvals for producing products from regulatory authorities are significantly contributing to the market growth. Furthermore, the escalating demand for effective treatment procedures at lowered costs and the reduced time for medical trials are positively influencing the market. Apart from this, the increasing individual interest in early diagnosis and the growing awareness regarding manufacturing quality drugs with advanced technologies are catalyzing the market. Moreover, the high demand for companion diagnostic products in oncology is anticipated to propel the market expansion. Besides, the rising expenditure on healthcare and clinical trials and the rapid advancements in bioscience are strengthening the market. Additionally, the growing efforts by the governments of various countries to spread awareness about the available medical treatments are bolstering the market. Looking forward, the market value is projected to reach USD 9.9 Billion by 2033, expanding at a CAGR of 16.4% during 2025-2033.

Market Summary:

  • On the basis of the disease type, the market has been categorized into neurological disorders, cardiovascular diseases, immunological disorders, oncology diseases, and others.
  • Based on the technology, the market has been classified into polymerase chain reaction, immunohistochemistry, in-situ hybridization, sequencing, and others.
  • Based on the end user, the market has been segmented into hospitals and clinics, diagnostic laboratories, and others.
  • On the basis of the region, the market has been divided into North America (the United States and Canada), Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others), Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others), Latin America (Brazil, Mexico, and others) and the Middle East and Africa.
  • The competitive landscape of the market has been studied in the report with detailed profiles of the key players operating in the market. Some of the key players include Abbott Laboratories, Agilent Technologies Inc., AmeriPath Inc (Quest Diagnostics Incorporated), Beckman Coulter Inc. (Danaher Corporation), Becton Dickinson and Company, F. Hoffmann-La Roche AG, General Electric Company, Illumina Inc., Myriad Genetics Inc., Pfizer Inc., Qiagen N.V. and Thermo Fisher Scientific Inc.

Report Scope:

Report Features Details
Base Year of the Analysis 2024
 Historical Period 2019-2024
Forecast Period 2025-2033
Units Billion USD
Segment Coverage Disease Type, Technology, End User, Region
Region Covered  Asia Pacific, Europe, North America, Latin America, Middle East and Africa
Countries Covered United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
Companies Covered Abbott Laboratories, Agilent Technologies Inc., AmeriPath Inc (Quest Diagnostics Incorporated), Beckman Coulter Inc. (Danaher Corporation), Becton Dickinson and Company, F. Hoffmann-La Roche AG, General Electric Company, Illumina Inc., Myriad Genetics Inc., Pfizer Inc., Qiagen N.V. and Thermo Fisher Scientific Inc.
Customization Scope 10% Free Customization
Post-Sale Analyst Support 10-12 Weeks
Delivery Format PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)


About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact Us:

IMARC Group
30 N Gould St, Ste 
Sheridan, WY (Wyoming) 82801 USA
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-753-713-2163 | Asia: +91-120-433-0800

Need more help?

  • Speak to our experienced analysts for insights on the current market scenarios.
  • Include additional segments and countries to customize the report as per your requirement.
  • Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  • For further assistance, please connect with our analysts.
Global Theranostics Market to Grow at 16.4% During 2025-2033, Impelled by Increasing Prevalence of Cancer
Purchase Options New Year Sale
Benefits of Customization
  • Personalize this research
  • Triangulate with your data
  • Get data as per your format and definition
  • Gain a deeper dive into a specific application, geography, customer, or competitor
  • Any level of personalization

Get in Touch With Us

UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-714-6104

Email: sales@imarcgroup.com

Client Testimonials